This therapy is commonly used in chronic conditions that require long-term immune support.

HyQvia is commonly used in immunodeficiency syndromes that present with profound or chronic deficiency of protective antibodies (IgG), and is considered relevant in primary immunodeficiency and certain secondary immunodeficiencies. It is also relevant as a maintenance therapy for adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

This approach provides supportive relief that helps ease the overall symptom burden, and is relevant for managing symptoms that interfere with daily comfort, such as frequent, severe, or recurrent systemic infections, or muscle weakness, numbness, and functional impairment linked to chronic nerve damage.

The use of this therapy supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Symptomatic Support

Regulatory References

1. European Medicines Agency (EMA) Overview

Official Eligibility and Restrictions

HyQvia eligibility is strictly defined by regulatory bodies and relies on age, indication, immune status, and co-existing medical conditions.

These rules ensure the medicine is only administered to patient groups for whom safety and use have been formally established by governmental regulatory agencies.

HyQvia Interactions with other medicines and products

Before starting treatment with HyQvia, it is essential to inform your healthcare provider about all medications, supplements, and vaccines you are currently receiving or plan to receive. This includes over-the-counter medicines and herbal products.

Vaccine Interactions

The immune globulin component of HyQvia may interfere with the effectiveness of certain live attenuated virus vaccines, such as those for measles, mumps, and rubella (MMR), and chickenpox (varicella). The passive transfer of antibodies can temporarily prevent the vaccine from producing an effective immune response. Your healthcare provider may recommend delaying live virus vaccinations for a certain period, typically up to one year, after HyQvia administration.

Other Potential Interactions

Since HyQvia contains hyaluronidase, which temporarily aids in the dispersion of the medication, it may theoretically affect the absorption of other subcutaneously administered medicines. Discuss any concurrent subcutaneous treatments with your doctor.

Additionally, caution is advised regarding medications that may increase the risk of blood clots (thrombosis), as immune globulin products, including HyQvia, have been associated with this risk. Your doctor will assess your individual risk factors, such as a history of cardiovascular disease, use of estrogens, or specific underlying conditions, and monitor you closely.

How HyQvia Works

Functional IgG Antibody Mechanism

The core mechanism involves the systemic delivery of Human Normal Immunoglobulin (IgG), a broad spectrum of functional antibodies that function as the active protein component. These molecules confer passive immunization by directly binding to and neutralizing pathogens, and by engaging Fc receptors (FcR) on immune cells to modulate the complement cascade and overall immune system signaling. This action results in the systemic presence of functional antibody molecules and contributes to the modulation of immune system signaling towards homeostasis.

Transient Extracellular Matrix Disassembly

The second mechanism is the localized, physical action of the Recombinant Human Hyaluronidase ( rHuPH20) enzyme. Its sole biological target is Hyaluronic Acid (HA), a key structural polymer in the subcutaneous tissue. rHuPH20 catalyzes the enzymatic hydrolysis of HA, causing a rapid, transient reduction in tissue viscosity and resistance.

Facilitated Systemic Uptake Synergy

These two mechanisms are intrinsically linked in a causal chain. The enzyme-mediated transient tissue permeability physically enables the effective dispersion of the large volume of the IgG solution, overcoming the natural constraint of the tissue. This synergy promotes the systemic transfer of high concentrations of the IgG component, which is necessary for its mechanistic action.

How to Use HyQvia: Official Administration Guidelines

HyQvia is administered only by the subcutaneous (SC) route; it must not be given intravenously or intramuscularly. Therapy should be initiated and monitored under the supervision of a physician experienced in treating immunodeficiency or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Patients or caregivers may be trained to self-administer at home after appropriate instruction from a healthcare professional.

Preparation and Dosing

Before use, both components (Immune Globulin [IG] and Recombinant Human Hyaluronidase [Hy]) must be allowed to reach room temperature. Vials should be visually inspected for discoloration or particulate matter, and they must not be shaken.

• Dosing Schedule: The dose is individualized based on the patient's weight and previous treatment. The typical dosing interval is every 3 or 4 weeks.
• Ramp-Up Schedule: Treatment starts with a gradual increase in dose and decrease in frequency (ramp-up) over the first few infusions to reach the full maintenance dose, ensuring patient tolerance. Doses are calculated to maintain the same weekly equivalent dose as the prior therapy.
• Missed Dose: If a patient misses a dose, administer the missed dose as soon as possible and then resume scheduled treatments as applicable.

Procedural Steps

Administration requires the use of an infusion pump. The two drug components must be administered sequentially through the same subcutaneous needle set:

1. Infuse the Hyaluronidase (Hy) component first. The full content of the Hy vial(s) is infused at a constant rate per site, regardless of the IG dose.
2. Infuse the Immune Globulin (IG) component second. The IG component is infused through the same needle set, beginning within 10 minutes after the Hy infusion is completed.

The suggested infusion site(s) are the middle to upper abdomen or thighs. The total dose may be administered at up to three infusion sites per infusion day, with specific maximum volume limits per site and per infusion day.

Research Evidence / Overview of Studies for HyQvia

Evidence for Primary Immunodeficiency Syndromes (Replacement Therapy)

The research available for Primary Immunodeficiency (PI) syndromes was conducted to evaluate its use in replacement therapy. The main studies were designed as pivotal, non-controlled, open-label clinical trials. This means the trials observed a group of patients receiving the treatment to see if the outcome met a specific, predefined scientific criteria for infection prevention.

Researchers examined outcomes related to acute or disruptive episodes, monitoring the annualized rate of acute serious bacterial infections (ASBIs). Studies also monitored the levels of protective antibodies (IgG) in the blood, known as pharmacokinetics. Findings described patterns observed in the studies, reporting that the infection rates were consistent with the predefined criteria for replacement therapy. However, direct comparative evidence is not available from these core trials.

Evidence for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Maintenance Therapy)

The research structure available for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) was conducted to evaluate its use as a maintenance therapy in adults, and is based on a study design involving randomization and placebo control. Studies explored the treatment's use in patients with conditions characterized by fluctuating or episodic manifestations.

Researchers primarily examined the prevention of disease relapse, measuring outcomes reflecting daily functioning or activity level using the INCAT disability score. Findings described patterns observed in the randomized trial, reporting a lower proportion of relapse events in the treatment group compared to the placebo group. A key aspect of this research is that the study population was restricted to adults with CIDP who had previously demonstrated stabilization on standard intravenous immunoglobulin (IVIG) therapy.

What the Research Does Not Yet Fully Characterize

Key research limitations include the fact that CIDP findings apply only to populations stabilized on IVIG; the evidence does not determine whether the product is appropriate for use as an induction therapy (a first-time treatment). Additionally, comparative evidence is lacking between this treatment and other immunoglobulin products administered subcutaneously. Data have not been collected for children and adolescents with CIDP.

The official requirements for the storage and disposal of the HyQvia dual vial unit are strictly defined by regulatory labeling to maintain product integrity and ensure proper handling.

Storage Requirements

The product must be stored in a refrigerator, maintaining a temperature range between 2 C and 8 C (36 F to 46 F), and it is mandatory not to freeze the vials. To protect the solution from light, the dual vial unit must remain in its original carton during storage. While primary storage is refrigerated, the product may be kept at room temperature, up to 25 C (77 F), for a single, maximum period of 3 months (90 days). Once removed from the refrigerator and stored at room temperature, the vials must not be returned to the refrigerator. The drug must be kept out of the sight and reach of children.

Disposal

Official disposal protocols require that any unused product be discarded according to local standards for biohazard products. All used needles and syringes must be disposed of promptly and correctly in a designated sharps container.